This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bruker (BRKR) Set to Acquire PhenomeX in an All-Cash Deal
by Zacks Equity Research
Bruker (BRKR) initiates its entry into since-cell biology research solutions with the acquisition of PhenomeX.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.
Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Haemonetics (HAE) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
BellRing Brands Inc. (BRBR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
BellRing Brands (BRBR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of a solid foundation for innovative therapies.
Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test
by Zacks Equity Research
Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.
Abbott (ABT) Gains in Core Diagnostics With FDA Nod for Alinity H
by Zacks Equity Research
Abbott's (ABT) Alinity h-series not only delivers technological innovation but also addresses the realistic challenges faced by modern healthcare systems.
Abbott (ABT) EPD Arm Grows, Low Testing Sales Play Spoilsport
by Zacks Equity Research
Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and acquisitions.
Syneos Health (SYNH) to Go Private, Reports Q2 Performance
by Zacks Equity Research
Syneos Health (SYNH) announces shareholders' approval for the impending merger and releases second-quarter 2023 financial results.
Medtronic (MDT) Rides on Strong Global Growth, New Launches
by Zacks Equity Research
Medtronic (MDT) is gaining from positive sales momentum with the rollout of its differentiated Hugo robotic system in many international markets.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and technological investments.
New Strong Buy Stocks for August 10th
by Zacks Equity Research
GM, KB, CRBG, AXS and HAE have been added to the Zacks Rank #1 (Strong Buy) List on August 10, 2023.
Haemonetics (HAE) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
The robust volume growth and price benefits in the Plasma business drive Haemonetics' (HAE) fiscal first-quarter performance.
Haemonetics (HAE) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.
Haemonetics (HAE) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 38.16% and 4.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics
by Zacks Equity Research
Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics are part of the Zacks Industry Outlook article.
Globus Medical (GMED) Gains on Innovation, Strategic Deal
by Zacks Equity Research
Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) based on the strong performances of the Bruker BioSpin Group.
4 Medical Product Stocks to Buy Amid Recovering Prospects
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. ABT, SYK, ZBH and HAE are well poised to gain from the favorable factors.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HAE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Haemonetics Corporation (HAE) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business.